AngioJet Thrombectomy System
Boston Scientific Corp · Decision date Aug 1, 2025
What did the FDA decide?
FDA records P980037/S095 as a supplement to PMA P980037, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 1, 2025.
FDA approval order statement
implementing final functional re-testing at the Dorado facility
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Aug 1, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P980037/S095
- Regulatory pathway
- PMA supplement
- Applicant
- Boston Scientific Corp
- Product code
- MCX
- Decision code
- OK30
- Decision date
- Aug 1, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: CATHETER, CORONARY, ATHERECTOMY.
- Applicant
- Boston Scientific Corp
- Product code
- MCX
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P980037/S095 received
Application receipt date recorded by FDA.
P980037/S095 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P980037. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code MCX
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ROTAPRO Rotational Atherectomy SystemsP900056/S226 | Boston Scientific Corp | PMA supplement | Oct 21, 2026 | FDA |
ROTAPRO Rotational Atherectomy SystemP900056/S229 | Boston Scientific Corp | PMA supplement | Oct 21, 2026 | FDA |
ROTAPRO Rotational Atherectomy SystemP900056/S228 | Boston Scientific Corp | PMA supplement | Oct 20, 2026 | FDA |
ROTABLATOR Rotational Atherectomy SystemP900056/S225 | Boston Scientific Corp | PMA supplement | May 6, 2026 | FDA |
| Boston Scientific Corp | PMA supplement | Apr 9, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corp
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- One Scimed Pl., Maple Grove, MN, 55311
Sources and methodology
- Original FDA record: P980037/S095
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



